Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Elife ; 92020 12 23.
Article in English | MEDLINE | ID: mdl-33355532

ABSTRACT

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in SMARCA4 (BRG1), one of the two mutually exclusive ATPases of the SWI/SNF chromatin remodeling complex. To address the role that BRG1 loss plays in SCCOHT tumorigenesis, we performed integrative multi-omic analyses in SCCOHT cell lines +/- BRG1 reexpression. BRG1 reexpression induced a gene and protein signature similar to an epithelial cell and gained chromatin accessibility sites correlated with other epithelial originating TCGA tumors. Gained chromatin accessibility and BRG1 recruited sites were strongly enriched for transcription-factor-binding motifs of AP-1 family members. Furthermore, AP-1 motifs were enriched at the promoters of highly upregulated epithelial genes. Using a dominant-negative AP-1 cell line, we found that both AP-1 DNA-binding activity and BRG1 reexpression are necessary for the gene and protein expression of epithelial genes. Our study demonstrates that BRG1 reexpression drives an epithelial-like gene and protein signature in SCCOHT cells that depends upon by AP-1 activity.


Subject(s)
Carcinoma, Small Cell/pathology , DNA Helicases/genetics , Hypercalcemia/pathology , Nuclear Proteins/genetics , Ovarian Neoplasms/metabolism , Transcription Factor AP-1/metabolism , Transcription Factors/genetics , Biomarkers, Tumor/analysis , Carcinoma, Small Cell/genetics , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , DNA Helicases/metabolism , Female , Humans , Hypercalcemia/genetics , Mutation/genetics , Nuclear Proteins/metabolism , Ovarian Neoplasms/pathology , Ovary/metabolism , Ovary/pathology , Transcription Factor AP-1/genetics , Transcription Factors/metabolism
2.
Int J Mol Sci ; 21(17)2020 Aug 20.
Article in English | MEDLINE | ID: mdl-32825309

ABSTRACT

Hyaluronic acid (HA) plays a vital role in the extracellular matrix of neural tissues. Originally thought to hydrate tissues and provide mechanical support, it is now clear that HA is also a complex signaling molecule that can regulate cell processes in the developing and adult nervous systems. Signaling properties are determined by molecular weight, bound proteins, and signal transduction through specific receptors. HA signaling regulates processes such as proliferation, differentiation, migration, and process extension in a variety of cell types including neural stem cells, neurons, astrocytes, microglia, and oligodendrocyte progenitors. The synthesis and catabolism of HA and the expression of HA receptors are altered in disease and influence neuroinflammation and disease pathogenesis. This review discusses the roles of HA, its synthesis and breakdown, as well as receptor expression in neurodevelopment, nervous system function and disease.


Subject(s)
Central Nervous System Diseases/metabolism , Hyaluronan Receptors/metabolism , Hyaluronan Synthases/metabolism , Hyaluronic Acid/physiology , Nervous System/growth & development , Animals , Brain/cytology , Brain/growth & development , Humans , Hyaluronic Acid/chemistry , Hyaluronoglucosaminidase/metabolism , Nervous System Physiological Phenomena , Neural Stem Cells/metabolism
3.
Glia ; 68(2): 263-279, 2020 02.
Article in English | MEDLINE | ID: mdl-31490574

ABSTRACT

Myelination delay and remyelination failure following insults to the central nervous system (CNS) impede axonal conduction and lead to motor, sensory and cognitive impairments. Both myelination and remyelination are often inhibited or delayed due to the failure of oligodendrocyte progenitor cells (OPCs) to mature into myelinating oligodendrocytes (OLs). Digestion products of the glycosaminoglycan hyaluronan (HA) have been implicated in blocking OPC maturation, but how these digestion products are generated is unclear. We tested the possibility that hyaluronidase activity is directly linked to the inhibition of OPC maturation by developing a novel modified flavonoid that functions as a hyaluronidase inhibitor. This compound, called S3, blocks some but not all hyaluronidases and only inhibits matrix metalloproteinase activity at high concentrations. We find that S3 reverses HA-mediated inhibition of OPC maturation in vitro, an effect that can be overcome by excess recombinant hyaluronidase. Furthermore, we find that hyaluronidase inhibition by S3 accelerates OPC maturation in an in vitro model of perinatal white matter injury. Finally, blocking hyaluronidase activity with S3 promotes functional remyelination in mice with lysolecithin-induced demyelinating corpus callosum lesions. All together, these findings support the notion that hyaluronidase activity originating from OPCs in CNS lesions is sufficient to prevent OPC maturation, which delays myelination or blocks remyelination. These data also indicate that modified flavonoids can act as selective inhibitors of hyaluronidase activity and can promote OPC maturation, making them excellent candidates to accelerate myelination or promote remyelination following perinatal and adult CNS insults.


Subject(s)
Demyelinating Diseases/pathology , Oligodendrocyte Precursor Cells/cytology , Oligodendroglia/metabolism , Remyelination/physiology , Animals , Cell Differentiation/physiology , Cells, Cultured , Mice , Mice, Inbred C57BL , Myelin Sheath/metabolism , Neurogenesis/physiology , Stem Cells/metabolism
4.
Mini Rev Med Chem ; 16(5): 391-403, 2016.
Article in English | MEDLINE | ID: mdl-26423697

ABSTRACT

The K-, N-, and HRas small GTPases are key regulators of cell physiology and are frequently mutated in human cancers. Despite intensive research, previous efforts to target hyperactive Ras based on known mechanisms of Ras signaling have been met with little success. Several studies have provided compelling evidence for the existence and biological relevance of Ras dimers, establishing a new mechanism for regulating Ras activity in cells additionally to GTP-loading and membrane localization. Existing data also start to reveal how Ras proteins dimerize on the membrane. We propose a dimer model to describe Ras-mediated effector activation, which contrasts existing models of Ras signaling as a monomer or as a 5-8 membered multimer. We also discuss potential implications of this model in both basic and translational Ras biology.


Subject(s)
ras Proteins/metabolism , Antineoplastic Agents/therapeutic use , Dimerization , Humans , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Mutation , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Signal Transduction , ras Proteins/antagonists & inhibitors , ras Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...